Irreversible treatment decisions under consideration of the research and development pipeline for new therapies

IIE Transactions (Institute of Industrial Engineers)

Volumn 42, Issue 9, 2010, Pages 632-642

  Shechter, Steven M ^a   Alagoz, Oguzhan ^b   Roberts, Mark S ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b University of Wisconsin Madison   (United States)

^c University of Pittsburgh   (United States)

Author keywords

Markov decision processes; Medical decision making; Research and development

Indexed keywords

MARKOV DECISION PROCESSES; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NUMERICAL EXAMPLE; OPTIMAL POLICIES; OPTIMAL TIME; QUALITY OF LIFE; RESEARCH AND DEVELOPMENT;

LEARNING ALGORITHMS; MARKOV PROCESSES; OPTIMIZATION; PIPELINES; RESEARCH;

DECISION MAKING;

EID: 77953625574     PISSN: 0740817X     EISSN: 15458830     Source Type: Journal    
DOI: 10.1080/07408170903468589     Document Type: Article

References (26)

1. Alagoz, O., Bryce, C.L., Shechter, S., Schaefer, A., Chang, C.C.H., Angus, D.C. and Roberts,M.S. (2005) Incorporating biological natural history in simulation models: empirical estimates of the progression of endstage liver disease. Medical Decision Making, 25(6), 620-632.
2. Alagoz, O., Maillart, L.M., Schaefer, A.J. and Roberts, M.S. (2004) The optimal timing of living-donor liver transplantation. Management Science, 50(10), 1420-1430.
3. Alagoz, O., Maillart, L.M., Schaefer, A.J. and Roberts, M.S. (2007a) Choosing among living-donor and cadaveric livers. Management Science, 53(11), 1702-1715.
4. Alagoz, O., Maillart, L.M., Schaefer, A.J. and Roberts, M.S. (2007b) Determining the acceptance of cadaveric livers using an implicit model of the waiting list. Operations Research, 55(1), 24-36.
5. American Cancer Society. (2007) Expectantmanagement (watchful waiting) and active surveillance. Available at: www.cancer.org/docroot/ CRI/content/CRI 2 4 4X Expectant Therapy Watching and Waiting 36.asp (accessed August 3, 2007)
6. Batun, S., Bhandari, A., Schaefer, A.J. and Roberts,M.S. (2007) Optimal liver acceptance for risk-sensitive patients.Working paper, University of Pittsburgh, Pittsburgh, PA.
7. Bertsekas, D.P. and Tsitsiklis, J.N. (2001) Dynamic Programming and Optimal Control, Athena Scientific, Belmont, MA.
8. Cher, D.J., Miyamoto, J. and Lenert, L.A. (1997) Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Medical Decision Making, 17, 340-350.
9. Cohen, C. (2003) Introduction: why do we need a new class ofHIV medications? Available at: www.thebody.com/fuzeon/intro.html (accessed August 1, 2007).
10. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22, 151-185.
11. Driffield, T. and Smith, P.C. (2007) A real options approach to watchful waiting: theory and an illustration. Medical Decision Making, 27, 178-188.
12. Gold, M.R., Patrick, D.L., Torrance, G.W., Fryback, D.G., Hadorn, D.C., Kamlet, M.S., Daniels, N. and Weinstein, M.C. (1996) Identifying and valuing outcomes, in Cost-Effectiveness in Health and Medicine, Gold, M.R., Siegel, J.E., Russell, L.B. andWeinstein,M.C. (eds). Oxford University Press, New York, NY, pp. 82-134.
13. Hopp, W.J. and Nair, S.K. (1994) Markovian deterioration and technological change. IIE Transactions, 26(6), 74-82.
14. Lee, C.P., Chertow, G.M. and Zenios, S.A. (2008) Optimal initiation and management of dialysis therapy. Operations Research, 56(6), 1428-1449.
15. Lee, E.K. and Zaider, M. (2008) Operations research advances cancer therapeutics. Interfaces, 38(1), 5-25.
16. Martinez, L.J. (2002) An overview of the drug approval process.Available at: www.thebody.com/content/art16845.html (accessed 15 October 2007).
17. Meijers-Heijboer, H., van Geel, B., van Putten,W.L.J.,Henzen-Logmans, S.C., Seynaeve, C., Menke-Pluymers, M.B.E., Bartels, C.C.M., Verhoog, L.C., Van den Ouweland, A.M.W., Niermeijer, M.F., Brekelmans, C.T.M. and Klijn, J.G.M. (2001) Breast cancer after prophylatic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 345(3), 159-164.
18. Pharmaceutical Research and Manufacturers of America. (2007). Available at: www.phrma.org (accessed 30 July 2007).
19. Puterman, M.L. (1994) Markov Decision Processes, Wiley, New York, NY.
20. Quang, T.S., Wallner, K.E., Herstein, P.R., Marie Palo, B., Walker, J.B. and Sutlief, S. (2007) Technologic evolution in the treatment of prostate cancer. Available at: www.cancernetwork.com/prostatecancer/ article/10165/62318 (accessed 15 May 2008).
21. Rajagopalan, S., Singh, M.R. and Morton, T.E. (1998) Capacity expansion and replacement in growing marketswith uncertain technological breakthroughs. Management Science, 44(1), 12-30.
22. Rasiel, E.B., Weinfurt, K.P. and Schulman, K.A. (2005) Can prospect theory explain risk-seeking behavior by terminally ill patients? Medical Decision Making, 25, 609-613.
23. Schaefer, A.J., Bailey, M.D., Shechter, S.M. and Roberts, M.S. (2004) Modeling medical treatment using Markov decision processes, in Operations Research and Health Care: A Handbook of Methods and Applications, Brandeau,M., Sainfort, F. and Pierskalla,W. (eds), Kluwer, Norwell, MA, pp. 597-616.
24. Shechter, S.M., Bailey, M.D., Schaefer, A.J. and Roberts, M.S. (2008) The optimal time to initiate HIV therapy under ordered health states. Operations Research, 56(1), 20-33.
25. Schechter, S.M. (2010) Treatment evolution and new standards of care: Implications for cost-effectiveness analysis. Medical DecisionMaking, forthcoming (appears in "Online First," March 30, 2010).
26. Yokota, F. and Thompson, K.M. (2004) Value of information literature analysis: a review of applications in health risk management. Medical Decision Making, 24, 287-298. (Pubitemid 38656313)